Cyanate as an inactivator of complement proteins

Area of Science:

• Immunology
• Biochemistry
• Complement System

Background:

• The complement system is vital for innate immunity and host defense.
• Sickle-cell disease patients often exhibit complement deficiencies, increasing infection risk.
• Sodium cyanate is being explored as a potential therapeutic for sickle-cell disease.

Purpose of the Study:

• To investigate the effect of sodium cyanate on complement protein function in human serum.
• To determine the mechanism and extent of complement inactivation by sodium cyanate.
• To assess the implications of cyanate-induced complement inactivation for sickle-cell disease patients.

Main Methods:

• Incubation of normal and sickle-cell patient serum with varying concentrations of sodium cyanate.
• Functional assays to measure the activity of complement components (C3, C5, C6, C7, C8, C9, C3b inactivator).
• Radiolabeling and binding studies with 14C-cyanate, circular dichroism, and electrophoresis to analyze protein modification and structure.

Main Results:

• Sodium cyanate functionally inactivated C3, C5, C6, C7, and C3b inactivator in a dose- and time-dependent manner.
• Inactivation occurred via direct carbamylation, as evidenced by protein binding and lack of structural changes in C3.
• Cyanate-treated C3 retained binding capacity but showed impaired immune adherence and agglutination functions.

Conclusions:

• Sodium cyanate directly inactivates critical components of the complement system.
• This inactivation, particularly of C3, may compromise host defense mechanisms.
• The findings highlight a significant concern for using sodium cyanate in sickle-cell disease patients due to potential exacerbation of immune deficiencies.